SOLV Stock Recent News

Contract drug manufacturer Thermo Fisher Scientific said on Tuesday it will buy Solventum's purification and filtration business for about $4.1 billion.

Accelerates Solventum's business transformation and sharpens focus on strategic areas for growth to deliver long-term shareholder value Strengthens balance sheet with proceeds to be used primarily for debt paydown ST. PAUL, Minn.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that the company has entered into a definitive agreement with Solventum (NYSE: SOLV) to acquire Solventum's Purification & Filtration business for approximately $4.1 billion in cash. Solventum's Purification & Filtration business is a leading provider of purification and filtration technologies used in the production of biologics as well as i.

BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics.

ST. PAUL, Minn. , Feb. 5, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) Solventum today announced that its AI-powered radiology speech reporting solution, Solventum™ Fluency™ for Imaging,  has ranked #1 in the 2025 Best in KLAS Awards—Software and Services Report  for the fifth time.

Company to host an Investor Day in March 2025 ST. PAUL, Minn.

Activist investor Nelson Peltz loves change. Seeking out undervalued and underperforming stocks, the billionaire often takes sizable positions in companies in a bid to unlock shareholder value via improvements in board representation, strategic overhauls, and operational efficiencies.

Nelson Peltz's Trian Fund Management said in a letter to shareholders on Wednesday that medical device maker Solventum's separation from 3M has not been living up to its potential.

Despite Performance Declines Since Spinning Out of 3M, Trian Believes Solventum Has Potential to Drive Significant Improvements as a Standalone Company

Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON , Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Elizabeth Mily as Chief Executive Officer. With more than 30 years of pharma, healthcare investment banking, and strategic leadership experience, Mily will leverage her mission-driven commitment to spearheading the next chapter of the Fund, guiding continued deployment of resources and supporting a co